3151
|
Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings. J Hypertens 2014; 32:681-92. [DOI: 10.1097/hjh.0000000000000071] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3152
|
Oparil S, Cushman WC, Lederle FA. Chlorthalidone Versus Hydrochlorothiazide in Hypertension Treatment: Do We Have the Evidence to Decide? Am J Kidney Dis 2014; 63:387-9. [DOI: 10.1053/j.ajkd.2013.11.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2013] [Accepted: 11/08/2013] [Indexed: 11/11/2022]
|
3153
|
Farsang C. Efficacy and tolerability of fixed-dose combination of perindopril/indapamide in type 2 diabetes mellitus: PICASSO trial. Adv Ther 2014; 31:333-44. [PMID: 24554346 PMCID: PMC3961595 DOI: 10.1007/s12325-014-0107-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2013] [Indexed: 12/14/2022]
Abstract
Background Hypertension and type 2 diabetes mellitus (T2DM) synergistically deteriorate the vascular environment, making blood pressure reduction challenging, and substantially increasing cardiovascular risk. Methods In the real-life, open-label, observational, PICASSO study, 9,257 hypertensive patients unsuccessfully treated with antihypertensives were switched to fixed-dose combination of perindopril 10 mg/indapamide 2.5 mg. In this subgroup analysis, we analyzed changes in blood pressure and laboratory parameters of 2,762 hypertensive patients with T2DM or pre-diabetes. Results After 3 months of treatment, significant decreases in office blood pressure were noted in the whole cohort (−27.0 ± 14.8/−12.7 ± 9.8 mmHg; p < 0.001). Significant decreases were also recorded in patients with grade 1 hypertension (19.2 ± 10.0/−9.4 ± 7.9 mmHg), grade 2 (29.2 ± 10.9/−13.3 ± 8.7 mmHg) and grade 3 (−45.1 ± 15.4/−21.5 ± 11.2 mmHg). Significant decreases in ambulatory blood pressure were also noted (n = 93). In patients previously treated with angiotensin-converting enzyme inhibitor ± hydrochlorothiazide or angiotensin receptor blocker ± hydrochlorothiazide, mean 24-h blood pressure decreased by 23.4 ± 13.9/11.5 ± 9.7 and 22.3 ± 8.7/10.4 ± 13.2 mmHg, respectively (p < 0.001). Treatment was well tolerated and the switch to treatment with perindopril/indapamide was associated with improvements in laboratory parameters. Conclusions Data from this diabetes subgroup analysis suggest that fixed combination of perindopril 10 mg/indapamide 2.5 mg should be routinely considered for the treatment of hypertension in diabetic patients who are unsuccessfully managed with other antihypertensive medications. Electronic supplementary material The online version of this article (doi:10.1007/s12325-014-0107-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Csaba Farsang
- St. Imre University Teaching Hospital, Tétényi u. 12-16, Budapest, 1115, Hungary,
| |
Collapse
|
3154
|
Galve E, Alegría E, Cordero A, Fácila L, Fernández de Bobadilla J, Lluís-Ganella C, Mazón P, de Pablo Zarzosa C, González-Juanatey JR. Temas de actualidad en cardiología: riesgo vascular y rehabilitación cardiaca. Rev Esp Cardiol 2014. [DOI: 10.1016/j.recesp.2013.09.021] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
3155
|
Detección de hipertrofia ventricular izquierda en la evaluación del riesgo cardiovascular del paciente hipertenso. Med Clin (Barc) 2014; 142:253-4. [DOI: 10.1016/j.medcli.2013.09.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2013] [Accepted: 09/19/2013] [Indexed: 11/17/2022]
|
3156
|
Schmieder RE, Volpe M, Waeber B, Ruilope LM. A guide for easy- and difficult-to-treat hypertension. Int J Cardiol 2014; 172:17-22. [DOI: 10.1016/j.ijcard.2013.12.125] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2013] [Accepted: 12/22/2013] [Indexed: 11/15/2022]
|
3157
|
Celic V, Tadic M, Suzic-Lazic J, Andric A, Majstorovic A, Ivanovic B, Stevanovic P, Iracek O, Scepanovic R. Two- and three-dimensional speckle tracking analysis of the relation between myocardial deformation and functional capacity in patients with systemic hypertension. Am J Cardiol 2014; 113:832-9. [PMID: 24528615 DOI: 10.1016/j.amjcard.2013.11.031] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Revised: 11/09/2013] [Accepted: 11/09/2013] [Indexed: 12/16/2022]
Abstract
The purpose of this study was to investigate left ventricular (LV) mechanics in hypertensive patients by 2- and 3-dimensional (3D) speckle tracking imaging, and determine the relation between the LV mechanics and functional capacity in this population. This cross-sectional study included 51 recently diagnosed, untreated, hypertensive patients, 49 treated subjects with well-controlled arterial hypertension, 52 treated participants with uncontrolled hypertension, and 50 controls adjusted by gender and age. All the subjects underwent 24-hour blood pressure monitoring, complete 2-dimensional and 3D examination, and cardiopulmonary exercise testing. 3D global longitudinal, circumferential, radial, and area strains were similar between the control group and well-controlled hypertensive patients but significantly decreased in comparison with patients with untreated or inadequately controlled hypertension. Similar findings were obtained for LV torsion and twist rate, whereas LV untwisting rate significantly deteriorated from the controls, across the well-controlled group, to the patients with untreated or uncontrolled hypertension. Peak oxygen uptake was significantly lower in the patients with untreated and uncontrolled hypertension than in the controls and the well-treated hypertensive patients. Peak oxygen uptake was independently associated with LV untwisting rate (β = 0.28, p = 0.03), 3D LV ejection fraction (β = 0.31, p = 0.024), and 3D global longitudinal strain (β = 0.26, p = 0.037) in the whole hypertensive population in our study. In conclusion, LV mechanics and functional capacity are significantly impaired in the patients with uncontrolled and untreated hypertension in comparison with the controls and the well-controlled hypertensive patients. Functional capacity is independently associated with 3D global longitudinal strain, LV untwisting rate, and 3D LV ejection fraction.
Collapse
|
3158
|
Abstract
Angiotensin II (Ang II) is today considered as one of the essential factors in the pathophysiology of cardiovascular disease, producing acute, hemodynamic and chronic, pleiotropic effects. Although now it is widely accepted that these chronic effects are important, Ang II was initially considered only a short-acting, vasoactive hormone. This view was modified a quarter of a century ago when Dr. Owens and his group published a paper in Circulation Research with initial evidence that Ang II can act as a growth factor that regulates cell hypertrophy. They showed in series of elegant experiments that Ang II promotes hypertrophy and hyperploidy of cultured rat aortic smooth muscle cells. However, Ang II had no effect on hyperplasia. These findings led to a paradigm shift in our understanding of the roles of growth factors and vasoactive substances in cardiovascular pathology and helped to redirect basic and clinical renin-angiotensin system research over the next twenty-five years. Ang II is now known to be a pleiotropic hormone that utilizes multiple signaling pathways to influence most processes that contribute to the development and progression of cardiovascular diseases, ranging from hypertrophy, endothelial dysfunction, cardiac remodeling, fibrosis, and inflammation to oxidative stress.
Collapse
Affiliation(s)
- Sasa Vukelic
- From the Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA
| | | |
Collapse
|
3159
|
Gouveia LAG, Marucci MDFN, Lebrão ML, Duarte YAO. Association between waist circumference (WC) values and hypertension, heart disease (HD) and diabetes, reported by the elderly--SABE Survey: Health, Wellness and Aging, 2000 and 2006. Arch Gerontol Geriatr 2014; 59:62-8. [PMID: 24708903 DOI: 10.1016/j.archger.2014.02.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Revised: 02/13/2014] [Accepted: 02/20/2014] [Indexed: 11/29/2022]
Abstract
The positive association between WC and systemic arterial hypertension (SAH), diabetes mellitus (DM) and HD calls for investigation in the elderly. The objective of the present study was to identify WC values, so as better to determine the risk of these diseases. This was a longitudinal study using the data of 405 elderly participants of the SABE Survey: Health, Well-being and Aging, undertaken in São Paulo, in 2000 and 2006. The study variables were WC, sex, age group, ethnicity, and body mass index (BMI) (2000) and SAH, DM and HD (2006). The area under the Receiver Operating Caracteristics (ROC) curve (AUC) and confidence intervals of 95% was used to estimate the performance of WC values in correctly discriminating among the elderly, according to the reference or not to diseases associated with WC. WC critical values were identified by the highest positive likelihood ratio (PLR), and negative likelihood ratio (NLR) equal to zero. The AUC showed the satisfactory performance of WC critical values in discriminating between reports of DM in individuals of 60-74 years of age. The WC critical values identified were ≥87 cm for women and ≥99 cm for men, which presented a better performance in relation to the AUC value than to the WC values commonly used. The WC critical values identified in this study showed better discriminatory power of foretelling reference to DM than did the WC values commonly used.
Collapse
Affiliation(s)
- Luiza A G Gouveia
- School of Public Health, University of São Paulo, Avenida Dr. Arnaldo, 715, Zip code: 01246-904 São Paulo, S.P. Brazil(1).
| | - Maria de Fátima N Marucci
- School of Public Health, University of São Paulo, Avenida Dr. Arnaldo, 715, Zip code: 01246-904 São Paulo, S.P. Brazil(1)
| | - Maria Lúcia Lebrão
- School of Public Health, University of São Paulo, Avenida Dr. Arnaldo, 715, Zip code: 01246-904 São Paulo, S.P. Brazil(1)
| | - Yeda Aparecida Oliveira Duarte
- Nursing School, University of São Paulo, Avenida Dr. Enéas de Carvalho Aguiar, 419 Zip code: 05403-000 São Paulo, S.P., Brazil(2)
| |
Collapse
|
3160
|
Posokhov IN, Konradi AO, Shlyakhto EV, Mamontov OV, Orlov AV, Rogoza AN. Day-to-day repeatability of the Pulse Time Index of Norm. MEDICAL DEVICES-EVIDENCE AND RESEARCH 2014; 7:29-33. [PMID: 24600253 PMCID: PMC3942216 DOI: 10.2147/mder.s58507] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
The pulse wave velocity (PWV) threshold for hypertensive target organ damage is presently set at 10 meters per second. New 24-hour monitors (eg, BPLab® and Vasotens®) provide several PWV measurements over a period of 24–72 hours. A new parameter, ie, the Pulse Time Index of Norm (PTIN), can be calculated from these data. The PTIN is defined as the percentage of a 24-hour period during which the PWV does not exceed 10 meters per second. The aim of the present study was to test the new PTIN for clinical feasibility using day-to-day repeatability analysis. Oscillometrically generated waveform files (n=85), which were previously used for research studies, were reanalyzed using the new 2013 version software of the Vasotens technology program, which enables calculation of PTIN. The intraclass correlation coefficient was 0.98 and Cronbach’s alpha was 0.97, indicating that the PTIN has excellent day-to-day repeatability and internal consistency. The present results show adequate repeatability, and PTIN assessment using the Vasotens technology appears to be feasible.
Collapse
Affiliation(s)
- Igor N Posokhov
- Hemodynamic Laboratory Ltd, Nizhniy Novgorod, Moscow, Russia
| | - Aleksandra O Konradi
- Almazov Federal Heart, Blood and Endocrinology Centre, Saint Petersburg, Moscow, Russia
| | - Eugeny V Shlyakhto
- Almazov Federal Heart, Blood and Endocrinology Centre, Saint Petersburg, Moscow, Russia
| | - Oleg V Mamontov
- Almazov Federal Heart, Blood and Endocrinology Centre, Saint Petersburg, Moscow, Russia
| | - Artemy V Orlov
- Department 65 Competitive System Analysis, National Research Nuclear University, Moscow, Russia
| | | |
Collapse
|
3161
|
Prediction of treatment-induced changes in target-organ damage using changes in clinic, home and ambulatory blood pressure. Hypertens Res 2014; 37:543-7. [DOI: 10.1038/hr.2014.24] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2013] [Revised: 09/23/2013] [Accepted: 09/30/2013] [Indexed: 11/08/2022]
|
3162
|
Total adiponectin is inversely associated with platelet activation and CHA₂DS₂-VASc score in anticoagulated patients with atrial fibrillation. Mediators Inflamm 2014; 2014:908901. [PMID: 24771985 PMCID: PMC3955592 DOI: 10.1155/2014/908901] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2013] [Accepted: 01/20/2014] [Indexed: 02/05/2023] Open
Abstract
Background. Adiponectin (APN) possesses anti-inflammatory and antiatherogenic effects. Atrial fibrillation (AF) is burdened by enhanced systemic inflammation and platelet activation, as documented by increased blood levels of soluble CD40L (sCD40L). The interplay between APN and platelet activation in AF is still undefined. Materials and Methods. Circulating levels of APN and sCD40L were measured in 257 anticoagulated nonvalvular AF patients. Exclusion criteria were as follows: prosthetic heart valves, cardiac revascularization in the previous year, severe cognitive impairment, chronic infectious or autoimmune diseases, and active cancer. Results. Mean age was 72.9 (±8.7) years and 41.6% were female. Serum APN and plasmatic sCD40L were inversely correlated (R −0.626, P < 0.001). A progressive increase of sCD40L across tertiles of CHA2DS2-VASc score was observed (rS 0.473, P < 0.001), whilst APN was inversely correlated (rS −0.463, P < 0.001). A multivariable linear regression analysis showed that CHA2DS2-VASc score (B −0.227, P < 0.001) and sCD40L (B −0.524, P < 0.001) correlated to APN. Conclusions. AF patients at high risk of stroke disclose low and high levels of APN and sCD40L, respectively, suggesting a role for APN if it favors platelet activation in vivo in this clinical setting. Enhancing APN levels may be a future goal to reduce the risk of vascular outcomes in AF patients.
Collapse
|
3163
|
Kirichenko LL, Gatsura SV, Golosova AN, Ovsyannikov KV, Budik OV, Fedorov AV. AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND CALCIUM ANTAGONIST COMBINATION IN PHARMACOTHERAPY OF ARTERIAL HYPERTENSION. КАРДИОВАСКУЛЯРНАЯ ТЕРАПИЯ И ПРОФИЛАКТИКА 2014. [DOI: 10.15829/1728-8800-2014-1-64-68] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
The paper focuses on the justification for preferential administration of antihypertensive combination therapy. Pharmacotherapeutic features of starting the treatment with a combination of angiotensin-converting enzyme inhibitors (ACEI) and calcium antagonists (AC) are reviewed. The authors also present the latest evidence on the ACEI/AC combination effects on such vascular parameters as microcirculation and endothelial dysfunction.
Collapse
Affiliation(s)
| | - S. V. Gatsura
- A.I. Evdokimov Moscow State Medico-Stomatological University
| | - A. N. Golosova
- A.I. Evdokimov Moscow State Medico-Stomatological University
| | | | - O. V. Budik
- A.I. Evdokimov Moscow State Medico-Stomatological University
| | - A. V. Fedorov
- Central Clinical Hospital, Russian Federal Customs Service, Moscow
| |
Collapse
|
3164
|
Bonadei I, Vizzardi E, D'Aloia A, Sciatti E, Raddino R, Metra M. Role of aliskiren on arterial stiffness and endothelial function in patients with primary hypertension. J Clin Hypertens (Greenwich) 2014; 16:202-6. [PMID: 24708382 DOI: 10.1111/jch.12262] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2013] [Revised: 12/10/2013] [Accepted: 12/12/2013] [Indexed: 12/21/2022]
Abstract
Arterial stiffness and endothelial dysfunction are important determinants of cardiovascular events in patients with arterial hypertension. There are few data regarding the role of aliskiren on the central hemodynamics and endothelial function in patients with uncontrolled arterial hypertension. The aim of this study was to assess the addition of aliskiren to other antihypertensive drug treatment for arterial stiffness and endothelial function. Thirty uncontrolled hypertensive patients (mean age, 60.4±12.2 years), without any other cardiovascular risk factors, were enrolled. Augmentation index (AIx) and carotid-femoral pulse wave velocity (cfPWV) by applanation tonometry and reactive hyperemia peripheral arterial tonometry (RH PAT) index using peripheral arterious tonometry at baseline and after 6 months of aliskiren titrated to 300 mg once a day was evaluated. The addition of aliskiren had no effect on values of central AIx (33.26±10.74% vs 28.86±10.74%; P=.36) but did significantly improve values of cfPWV (9.36±2.65 m/s vs 8.72±2.48 m/s; P=.04) and RH PAT index (1.64±0.57 vs 1.75±0.45; P=.05). In addition to improving systolic and diastolic blood pressure, the addition of aliskiren to concomitant antihypertensive drugs in uncontrolled hypertensive patients may be effective in improving aortic stiffness and endothelial function. These results encourage further studies to evaluate the use of aliskiren for cardiovascular prevention.
Collapse
Affiliation(s)
- Ivano Bonadei
- Department of Medical and Surgical, Radiological Sciences and Public Health Specialties, University of Study of Brescia, Brescia, Italy
| | | | | | | | | | | |
Collapse
|
3165
|
Laucevičius A, Rinkūnienė E, Petrulionienė Ž, Puronaitė R, Kasiulevičius V, Jatužis D, Ryliškytė L, Badarienė J, Čypienė A, Navickas R, Kizlaitis R, Gustienė O, Šlapikas R. Prevalence of high-risk profile in middle-aged subjects with arterial hypertension: A nationwide survey. Blood Press 2014; 23:281-7. [DOI: 10.3109/08037051.2014.883187] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
3166
|
Daikuhara H, Fukunaga K, Ohshima T. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study. DRUG DESIGN DEVELOPMENT AND THERAPY 2014; 8:219-26. [PMID: 24600204 PMCID: PMC3933665 DOI: 10.2147/dddt.s53253] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Purpose This open-label controlled study compared the therapeutic efficacy of three representative angiotensin II receptor blockers (ARBs) in hypertensive patients with type 2 diabetes attending a hospital outpatient clinic. The primary measure in this study was morning home blood pressure (BP). Patients and methods Two studies were done concurrently to investigate the effects of switching from two different ARBs to olmesartan. Patients prescribed candesartan (8 mg once daily in the morning) or telmisartan (40 mg once daily in the morning) for 16 weeks were switched to olmesartan (20 mg once daily in the morning) for 16 weeks. Then, they were switched back to candesartan (CO group) or telmisartan (TO group) for another 16 weeks. Results Data from all patients in the CO group (n=165) and the TO group (n=152) were analyzed. Clinic and morning home BP and urinary albumin levels showed a significant decrease from baseline at 16 weeks after switching to olmesartan in both the CO and the TO group (clinic BP, morning home diastolic BP, and urinary albumin, P<0.05; morning home systolic BP, P<0.01). In contrast, clinic BP, morning home BP, and urinary albumin were significantly increased again 16 weeks after switching back to candesartan or telmisartan (clinic BP, morning home diastolic BP, and urinary albumin, P<0.05; morning home systolic BP, P<0.01). No subjects experienced an adverse reaction that required withdrawal from the study. No adverse reactions attributable to the study drugs were observed. Conclusion Olmesartan is a promising ARB for BP control in hypertensive type 2 diabetics.
Collapse
Affiliation(s)
| | - Kensaku Fukunaga
- Department of Internal Medicine, Sakaide City Hospital, Kagawa, Japan
| | - Tomie Ohshima
- Department of Internal Medicine, Sakaide City Hospital, Kagawa, Japan
| |
Collapse
|
3167
|
Volpe M, de la Sierra A, Kreutz R, Laurent S, Manolis AJ. ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients. High Blood Press Cardiovasc Prev 2014; 21:137-47. [PMID: 24532183 DOI: 10.1007/s40292-014-0043-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2013] [Accepted: 01/25/2014] [Indexed: 01/07/2023] Open
Abstract
Hypertension is a major modifiable risk for the development of cardiovascular, cerebrovascular and renal diseases. Thus, effective treatment of high blood pressure is an important strategy for reducing disease burden; however, in spite of the availability of numerous effective therapies only 30-40 % of patients with hypertension achieve the recommended blood pressure goals of <140/90 mmHg. Lack of adherence to therapy and reluctance to intensify therapy are cited frequently to explain the discrepancy between potential and attained outcomes. Adherence is closely related to the tolerability, effectiveness and complexity of therapy. Therapeutic inertia may be influenced by concerns over tolerability, as well as the lack of clear preferences for therapies when managing patients with risk factors and comorbidities. Effective and well-tolerated single pill combination therapies are now available that improve adherence and simplify treatment. The combination of a renin-angiotensin system blocker with a calcium channel blocker and a diuretic improves adherence to therapy. We have devised a practical tool for orienting the application of well-tolerated single pill 2/3 drug fixed dose combination therapies in clinical situations commonly encountered when treating hypertensive patients. This approach employs the angiotensin receptor blocker olmesartan alone or in combinations with amlodipine and/or hydrochlorothiazide. This platform is based on clinical evidence, guidelines, best practice, and clinical experience where none of these is available. We believe it will increase the percentage of hypertensive patients who achieve blood pressure control when applied as part of an integrative approach that includes regular follow-up and instruction on lifestyle changes.
Collapse
Affiliation(s)
- Massimo Volpe
- Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Via di Grottarossa 1035-39, 00189, Rome, Italy,
| | | | | | | | | |
Collapse
|
3168
|
Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial. Lancet Neurol 2014; 13:364-73. [PMID: 24530176 DOI: 10.1016/s1474-4422(14)70018-3] [Citation(s) in RCA: 164] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
BACKGROUND High blood pressure is a prognostic factor for acute stroke, but blood pressure variability might also independently predict outcome. We assessed the prognostic value of blood pressure variability in participants of INTERACT2, an open-label randomised controlled trial (ClinicalTrials.gov number NCT00716079). METHODS INTERACT2 enrolled 2839 adults with spontaneous intracerebral haemorrhage (ICH) and high systolic blood pressure (150-220 mm Hg) without a definite indication or contraindication to early intensive treatment to reduce blood pressure. Participants were randomly assigned to intensive treatment (target systolic blood pressure <140 mm Hg within 1 h using locally available intravenous drugs) or guideline-recommended treatment (target systolic blood pressure <180 mm Hg) within 6 h of onset of ICH. The primary outcome was death or major disability at 90 days (modified Rankin Scale score ≥3) and the secondary outcome was an ordinal shift in modified Rankin Scale scores at 90 days, assessed by investigators masked to treatment allocation. Blood pressure variability was defined according to standard criteria: five measurements were taken in the first 24 h (hyperacute phase) and 12 over days 2-7 (acute phase). We estimated associations between blood pressure variability and outcomes with logistic and proportional odds regression models. The key parameter for blood pressure variability was standard deviation (SD) of systolic blood pressure, categorised into quintiles. FINDINGS We studied 2645 (93·2%) participants in the hyperacute phase and 2347 (82·7%) in the acute phase. In both treatment cohorts combined, SD of systolic blood pressure had a significant linear association with the primary outcome for both the hyperacute phase (highest quintile adjusted OR 1·41, 95% CI 1·05-1·90; ptrend=0·0167) and the acute phase (highest quintile adjusted OR 1·57, 95% CI 1·14-2·17; ptrend=0·0124). The strongest predictors of outcome were maximum systolic blood pressure in the hyperacute phase and SD of systolic blood pressure in the acute phase. Associations were similar for the secondary outcome (for the hyperacute phase, highest quintile adjusted OR 1·43, 95% CI 1·14-1·80; ptrend=0·0014; for the acute phase OR 1·46, 95% CI 1·13-1·88; ptrend=0·0044). INTERPRETATION Systolic blood pressure variability seems to predict a poor outcome in patients with acute intracerebral haemorrhage. The benefits of early treatment to reduce systolic blood pressure to 140 mm Hg might be enhanced by smooth and sustained control, and particularly by avoiding peaks in systolic blood pressure. FUNDING National Health and Medical Research Council of Australia.
Collapse
|
3169
|
Abstract
The Eighth Joint National Committee (JNC 8) guidelines on hypertension have generated great interest among physicians. These guidelines differ from those published in 2003 (the JNC 7) - in the document format, blood-pressure cut-off values, and recommendations for antihypertensive drug use. The JNC 8 have some limitations that could affect clinical practice.
Collapse
Affiliation(s)
- Giuseppe Mancia
- IRCCS Istituto Auxologico Italiano and University of Milano-Bicocca, Piazzale Brescia 20, Milan 20149, Italy
| |
Collapse
|
3170
|
Geraci G, Mulè G, Geraci C, Mogavero M, D’Ignoto F, Morreale M, Foraci AC, Cottone S. Association of renal resistive index with aortic pulse wave velocity in hypertensive patients. Eur J Prev Cardiol 2014; 22:415-22. [DOI: 10.1177/2047487314524683] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3171
|
Burnier M, Pruijm M, Wuerzner G, Santschi V. Drug adherence in chronic kidney diseases and dialysis. Nephrol Dial Transplant 2014; 30:39-44. [PMID: 24516224 DOI: 10.1093/ndt/gfu015] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Poor long-term adherence and persistence to drug therapy is universally recognized as one of the major clinical issues in the management of chronic diseases, and patients with renal diseases are also concerned by this important phenomenon. Chronic kidney disease (CKD) patients belong to the group of subjects with one of the highest burdens of daily pill intake with up to >20 pills per day depending on the severity of their disease. The purpose of the present review is to discuss the difficulties encountered by nephrologists in diagnosing and managing poor adherence and persistence in CKD patients including in patients receiving maintenance dialysis. Our review will also attempt to provide some clues and new perspectives on how drug adherence could actually be addressed and possibly improved. Working on drug adherence may look like a long and tedious path, but physicians and healthcare providers should always be aware that drug adherence is in general much lower than what they may think and that there are many ways to improve and support drug adherence and persistence so that renal patients obtain the full benefits of their treatments.
Collapse
Affiliation(s)
- Michel Burnier
- Department of Medicine, Service of Nephrology and Hypertension, University Hospital, Lausanne, Switzerland
| | - Menno Pruijm
- Department of Medicine, Service of Nephrology and Hypertension, University Hospital, Lausanne, Switzerland
| | - Gregoire Wuerzner
- Department of Medicine, Service of Nephrology and Hypertension, University Hospital, Lausanne, Switzerland
| | - Valerie Santschi
- La Source, School of nursing sciences, University of Applied Sciences Western Lausanne, Lausanne, Switzerland
| |
Collapse
|
3172
|
Palatini P. How should we manage a patient with masked hypertension? High Blood Press Cardiovasc Prev 2014; 22:11-6. [PMID: 24500867 DOI: 10.1007/s40292-014-0044-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2013] [Accepted: 01/28/2014] [Indexed: 01/02/2023] Open
Abstract
A number of studies have shown that masked hypertension (MH) confers an increased risk of target organ damage and of cardiovascular events suggesting that patients with MH would benefit from antihypertensive treatment. However, there is no general agreement about how this condition should be diagnosed. Although ambulatory blood pressure monitoring (ABPM) and self blood pressure measurement (SBPM) provide different and complementary clinical information, the recently published ESH/ESC guidelines for the management of arterial hypertension suggest that for initial assessment of the patient, SBPM may be more suitable in primary care and ABPM in specialist care. If SBPM provides borderline values it is advisable to confirm the diagnosis of MH with ABPM. As the prevalence of MH declines with repeated ABPMs the diagnosis of MH should be based on at least two ABPMs. Patients with MH should undergo a careful diagnostic work-up to assess the existence of additional risk factors including a worsened metabolic profile and the presence of target organ involvement. Treatment of the patient with MH should initially be addressed to improve the patient's lifestyle in order to decrease out-of-office blood pressure and to ameliorate metabolic data. If non-pharmacological measures are insufficient to normalize blood pressure, MH may benefit from pharmacological treatment but no clinical trial has been implemented as yet with the specific purpose of testing this hypothesis. Despite this lack of evidence, the 2013 ESH/ESC guidelines have recommended that in patients with MH also drug treatment should be considered because in patients with MH the risk of adverse outcome is very close to that in sustained hypertension. When ambulatory blood pressure is measured, pharmacological treatment may be modulated according to whether blood pressure is elevated during daytime hours or during sleep.
Collapse
Affiliation(s)
- Paolo Palatini
- Department of Medicine, University of Padova, via Giustiniani 2, 35128, Padua, Italy,
| |
Collapse
|
3173
|
Sleep-time ambulatory blood pressure as a novel therapeutic target for cardiovascular risk reduction. J Hum Hypertens 2014; 28:567-74. [DOI: 10.1038/jhh.2014.1] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2013] [Revised: 12/10/2013] [Accepted: 12/26/2013] [Indexed: 11/08/2022]
|
3174
|
Single-pill combination of telmisartan and hydrochlorothiazide: studies and pooled analyses of earlier hypertension treatment. High Blood Press Cardiovasc Prev 2014; 21:119-26. [PMID: 24493330 DOI: 10.1007/s40292-014-0041-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2013] [Accepted: 01/16/2014] [Indexed: 11/27/2022] Open
Abstract
Lowering blood pressure (BP) in patients with high blood pressure reduces cardiovascular risk. Studies support health benefits when BP goals are achieved earlier in the course of treatment. Many patients require combination therapy to achieve BP goals; initial use of combination therapy may improve earlier BP goal attainment. This analysis reports the results of a search of the Boehringer Ingelheim clinical trial database for randomized, double-blind studies of telmisartan/hydrochlorothiazide (T/H) combination therapy compared with blood pressure monotherapies. Nine studies were identified. This report examined six separate analyses of these nine studies (three analyses of individual trials; three analyses for which two trials each were pooled). The focus of this report is the BP effects of combination T/H therapy compared with respective monotherapies at the earliest available time points (Weeks 1, 2, 3 and/or 4). These analyses included a total of 5,358 patients. During these earlier time periods, combination T/H reduced systolic BP (SBP) and diastolic BP (DBP) significantly more than placebo or respective monotherapies in most treatment comparisons for patients initiated on monotherapy. Combination T/H also allowed significantly more patients to achieve BP (<140/90 mmHg), SBP (<140 mmHg), and DBP (<90 mmHg) goal attainment rates compared with placebo (p < 0.0002), and numerically higher compared with T or H monotherapy. In patients uncontrolled by monotherapy, combination T/H significantly reduced SBP/DBP more than monotherapy (p < 0.0001). Similarly, BP, SBP and DBP goal attainment rates were significantly higher with combination T/H therapy (p < 0.0022). Reported adverse events with T/H therapy were generally similar to monotherapy, and placebo. In summary, the six separate analyses of nine different trials demonstrated that T/H significantly lowered BP as early as 1-4 weeks after initiation of therapy, with greater BP lowering, and greater BP goal attainment than with monotherapies or placebo.
Collapse
|
3175
|
Gijón-Conde T, Graciani A, Banegas JR. Resistant hypertension: demography and clinical characteristics in 6,292 patients in a primary health care setting. ACTA ACUST UNITED AC 2014; 67:270-6. [PMID: 24774589 DOI: 10.1016/j.rec.2013.09.027] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2013] [Accepted: 09/10/2013] [Indexed: 11/17/2022]
Abstract
INTRODUCTION AND OBJECTIVES The prevalence of resistant hypertension has recently been reported, but there are no studies on its demography. This study aimed to examine the demography and clinical characteristics of resistant hypertension in a large sample of primary care patients. METHODS A cross-sectional study was performed of all computerized medical records of hypertensive patients in Health Area 6 of Madrid (Spain). Of 63 167 hypertensive patients, we selected 48 744 with prescription of antihypertensive medication; of these, we selected those who met the American Heart Association criteria for resistant hypertension. RESULTS A total of 6292 patients had resistant hypertension, representing 9.9% of all hypertensive patients and 12.9% of those treated. A total of 5.5% were < 50 years (8.5% men and 3.2% women) and 24.7% were > 80 years (15.8% men and 31.4% women) (P < .001). In patients < 50 years, resistant hypertension was associated with male sex (odds ratio female/male = 0.006; 95% confidence interval, 0.000-0.042; P < .001), systolic blood pressure, obesity, stroke, and chronic kidney disease (P < .001). In those > 80 years, resistant hypertension was associated with female sex (odds ratio female/male = 1.27; 95% confidence interval, 1.08-1,10; P = .004), systolic blood pressure, diabetes mellitus, obesity, chronic kidney disease, coronary heart disease, and atrial fibrillation (P < .001). More than 50% of patients > 80 years with resistant hypertension had cardiovascular disease. CONCLUSIONS One in 4 patients with resistant hypertension is > 80 years. Resistant hypertension is associated with cardiovascular disease, age < 50 years in men and age > 80 years in women. There is a high proportion of cardiovascular disease in elderly patients with resistant hypertension.
Collapse
Affiliation(s)
- Teresa Gijón-Conde
- Centro de Salud Universitario Cerro del Aire, Dirección Asistencial Noroeste, Majadahonda, Madrid, Spain; Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid/IdiPaz, CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
| | - Auxiliadora Graciani
- Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid/IdiPaz, CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - José R Banegas
- Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid/IdiPaz, CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| |
Collapse
|
3176
|
Tadic M, Majstorovic A, Pencic B, Ivanovic B, Neskovic A, Badano L, Stanisavljevic D, Scepanovic R, Stevanovic P, Celic V. The impact of high-normal blood pressure on left ventricular mechanics: a three-dimensional and speckle tracking echocardiography study. Int J Cardiovasc Imaging 2014; 30:699-711. [DOI: 10.1007/s10554-014-0382-3] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2013] [Accepted: 01/27/2014] [Indexed: 12/18/2022]
|
3177
|
|
3178
|
|
3179
|
Bramlage P, Buhck H, Zemmrich C. Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impact. Clin Drug Investig 2014; 34:241-9. [PMID: 24482018 DOI: 10.1007/s40261-014-0169-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND AND OBJECTIVES Safety and efficacy of the fixed-dose combination candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg has been demonstrated in a number of randomized clinical trials. Because stringent inclusion and exclusion criteria prohibit many high-risk patients from being investigated in clinical trials we aimed to assess the effectiveness, tolerability, and safety in a large unselected cohort of high-risk patients in primary care. The primary objective was the efficacy of candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in lowering the office-based blood pressure (BP). Secondary objectives were changes of metabolic parameters and safety. METHODS A multicenter, non-interventional study of patients with a BP ≥ 140 mmHg systolic and/or 90 mmHg diastolic and additional cardiovascular risk factors. Patients received the fixed-dose combination of candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg for 24 weeks. RESULTS A total of 3,390 patients with a mean age of 61.7 ± 10.6 years, 57.8 % being male, and a mean body mass index of 29.7 kg/m(2) were documented. Of these, 70.9 % had at least one additional cardiovascular risk factor such as coronary artery disease (45.5 %) or diabetes mellitus (44.5 %). Baseline BP was 159.6 ± 15.3 over 93.5 ± 9.5 mmHg. BP at 24 weeks was reduced by 32.3 ± 15.8 systolic and 16.1 ± 10.2 mmHg diastolic compared with baseline (p < 0.001 each). Systolic BP (SBP) and diastolic BP (DBP) was normalized (<140/<90 mmHg) in 57.4 % of non-diabetic patients. An SBP <140 mmHg or SBP reduction of ≥ 20 mmHg was achieved by 77.9 % non-diabetic patients. Fasting plasma glucose (-5.9 mg/dL), glycosylated hemoglobin (-0.18 %), low-density lipoprotein cholesterol (-8.5 mg/dL) and triglycerides (-20.3 mg/dL) were reduced significantly, high-density lipoprotein was increased by 0.18 %, while potassium and creatinine levels remained stable. The proportion of patients with adverse drug reactions (ADRs) was 1.3 % (n = 61 events in 45 patients). There were ten serious ADRs in eight patients; four patients died without causal relationship to study drug. CONCLUSIONS The results confirm previous randomized clinical trial data supporting the effectiveness, tolerability, and safety of this fixed-dose combination in an unselected patient population with high cardiovascular risk.
Collapse
Affiliation(s)
- Peter Bramlage
- Institut für Pharmakologie und präventive Medizin, Menzelstrasse 21, 15831, Mahlow, Germany,
| | | | | |
Collapse
|
3180
|
Seif F, Patel SR, Walia HK, Rueschman M, Bhatt DL, Blumenthal RS, Quan SF, Gottlieb DJ, Lewis EF, Patil SP, Punjabi NM, Babineau DC, Redline S, Mehra R. Obstructive sleep apnea and diurnal nondipping hemodynamic indices in patients at increased cardiovascular risk. J Hypertens 2014; 32:267-75. [PMID: 24351803 PMCID: PMC4096765 DOI: 10.1097/hjh.0000000000000011] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
RATIONALE We hypothesized increasing obstructive sleep apnea (OSA) severity would be associated with nondipping blood pressure (BP) in increased cardiovascular disease (CVD) risk. METHODS Baseline data from 298 cardiology patients recruited for a multicenter randomized controlled trial were examined. Dipping was defined as a sleep-related BP or heart rate (HR) reduction of at least 10%. Logistic regression models were fit, adjusting for age, sex, race, BMI, CVD risk factors, CVD, and study site. RESULTS There was a statistically significant 4% increase in the odds of nondipping SBP per 1-unit increase in both apnea hypopnea index (AHI) and oxygen desaturation index (ODI). There was no significant relationship between AHI and nondipping mean arterial pressure (MAP); however, a 3% increase in the odds of nondipping MAP per 1-unit increase in ODI was observed [odds ratio (OR) = 1.03; 95% confidence interval (CI) 1.00-1.05]. At severe OSA levels, a 10 and 4% increase in odds of nondipping DBP per 1-unit increase in AHI and ODI were observed, respectively. A 6% [OR = 1.06; 95% CI (1.01-1.10)] increase in nondipping HR odds was observed with each increase in ODI until the upper quartile of ODI. CONCLUSION In patients at cardiovascular risk and moderate-to-severe OSA, increasing AHI and/or ODI were associated with increased odds of nondipping SBP and nondipping MAP. More severe levels of AHI and ODI also were associated with nondipping DBP. These results support progressive BP burden associated with increased OSA severity even in patients managed by cardiology specialty care.
Collapse
Affiliation(s)
- Fadi Seif
- Department of Medicine, Case School of Medicine, Cleveland, Ohio
| | - Sanjay R. Patel
- Brigham and Women’s Hospital, Boston, Massachusetts
- Beth Israel Deaconess Medical Center, Boston, Massachusetts
| | - Harneet K. Walia
- Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA
| | | | - Deepak L. Bhatt
- Brigham and Women’s Hospital, Boston, Massachusetts
- VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts
| | | | | | - Daniel J. Gottlieb
- Brigham and Women’s Hospital, Boston, Massachusetts
- VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts
| | | | | | | | - Denise C. Babineau
- Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA
| | - Susan Redline
- Brigham and Women’s Hospital, Boston, Massachusetts
- Beth Israel Deaconess Medical Center, Boston, Massachusetts
| | - Reena Mehra
- Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA
| |
Collapse
|
3181
|
Artom N, Montecucco F, Mach F, Dallegri F, Pende A. Angiotensin II receptor antagonists in acute coronary syndromes. Eur J Clin Invest 2014; 44:219-30. [PMID: 24289238 DOI: 10.1111/eci.12198] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Accepted: 11/01/2013] [Indexed: 12/25/2022]
Abstract
BACKGROUND It is well known that inappropriate or exaggerated activity of the renin-angiotensin system might contribute to the development of systemic hypertension with consequent organ injury and associated increased risk of acute cardiovascular (CV) diseases. This review will discuss evidence form basic research and clinical studies, investigating the efficacy of angiotensin II receptor blockers (ARBs) in the management of acute coronary syndromes (ACS). MATERIALS AND METHODS This narrative review is based on the material found on MEDLINE and PubMed up to June 2013. We looked for the terms 'angiotensin, AT1 receptor, ACE inhibitors' in combination with 'acute coronary syndromes, acute myocardial infarction, pathophysiology'. RESULTS Preclinical studies showed relevant protective effects of ARBs to reduce adverse cardiac remodelling in animal models of acute cardiac ischaemia. However, although recommended in Consensus guidelines as a good alternative to angiotensin-converting enzyme inhibitors (ACEIs), clinical studies did not confirm a superior efficacy of the ARBs as compared to ACEIs. As a matter of fact for some authors, these drugs might potentially have deleterious effects increasing the CV risk. CONCLUSIONS Emerging evidence from clinical trials suggests that the use of ARBs in ACS might be controversial, and caution should be used for their clinical use to replace ACEIs in ACS.
Collapse
Affiliation(s)
- Nathan Artom
- First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | | | | | | | | |
Collapse
|
3182
|
Alessi A, Brandão AA, de Paiva AMG, Nogueira ADR, Feitosa A, Gonzaga CDC, Amodeo C, Mion D, de Souza DDSM, Barbosa E, Lima Junior E, Nobre F, Fuchs FD, Chaves Junior H, Schneider JC, Gemelli J, Villela-Martin JF, Scala LCN, Gomes MAM, Malachias MVB, de Morais NS, Moreira Filho O, Passarelli Junior O, Jardim PCBV, Miranda RD, Póvoa R, Fuchs SC, Baiocchi S, Jardim TV, Barroso WKS. I Brazilian position paper on prehypertension, white coat hypertension and masked hypertension: diagnosis and management. Arq Bras Cardiol 2014; 102:110-8. [PMID: 24676366 PMCID: PMC3987343 DOI: 10.5935/abc.20140011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2013] [Revised: 12/03/2013] [Accepted: 12/03/2013] [Indexed: 01/22/2023] Open
Affiliation(s)
- Alexandre Alessi
- Brazilian Society of Cardiology Arterial Hypertension Department
| | | | | | | | - Audes Feitosa
- Brazilian Society of Cardiology Arterial Hypertension Department
| | | | - Celso Amodeo
- Brazilian Society of Cardiology Arterial Hypertension Department
| | - Decio Mion
- Brazilian Society of Cardiology Arterial Hypertension Department
| | | | - Eduardo Barbosa
- Brazilian Society of Cardiology Arterial Hypertension Department
| | | | - Fernando Nobre
- Brazilian Society of Cardiology Arterial Hypertension Department
| | | | | | | | - João Gemelli
- Brazilian Society of Cardiology Arterial Hypertension Department
| | | | | | | | | | | | | | | | | | | | - Rui Póvoa
- Brazilian Society of Cardiology Arterial Hypertension Department
| | | | - Sergio Baiocchi
- Brazilian Society of Cardiology Arterial Hypertension Department
| | | | | |
Collapse
|
3183
|
Abstract
Older adults with type 1 diabetes are at high risk for severe hypoglycemia and may have serious comorbid conditions. Problems with cognition, mobility, dexterity, vision, hearing, depression, and chronic pain interfere with the ability to follow complex insulin regimens. With the development of geriatric syndromes, unpredictable eating, and frailty, treatment regimens must be modified with the goal of minimizing hypoglycemia and severe hyperglycemia and maximizing quality of life.
Collapse
|
3184
|
Gregori M, Tocci G, Giammarioli B, Befani A, Ciavarella GM, Ferrucci A, Paneni F. Abnormal Regulation of Renin Angiotensin Aldosterone System Is Associated With Right Ventricular Dysfunction in Hypertension. Can J Cardiol 2014; 30:188-94. [DOI: 10.1016/j.cjca.2013.11.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2013] [Revised: 11/03/2013] [Accepted: 11/04/2013] [Indexed: 10/26/2022] Open
|
3185
|
Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Paul Taggart D, van der Wall EE, Vrints CJ, Luis Zamorano J, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Anton Sirnes P, Luis Tamargo J, Tendera M, Torbicki A, Wijns W, Windecker S, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, González-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Dalby Kristensen S, Lancellotti P, Pietro Maggioni A, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Anton Sirnes P, Gabriel Steg P, Timmis A, Wijns W, Windecker S, Yildirir A, Luis Zamorano J. Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable. Rev Esp Cardiol 2014. [DOI: 10.1016/j.recesp.2013.11.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
3186
|
Stergiou GS, Karpettas N, Destounis A, Tzamouranis D, Nasothimiou E, Kollias A, Roussias L, Moyssakis I. Home blood pressure monitoring alone vs. combined clinic and ambulatory measurements in following treatment-induced changes in blood pressure and organ damage. Am J Hypertens 2014; 27:184-92. [PMID: 24190902 DOI: 10.1093/ajh/hpt206] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND Out-of-office blood pressure (BP) measurement using home BP (HBP) or ambulatory BP (ABP) monitoring is often necessary for the accurate evaluation of hypertension. These methods have several similarities but also have major differences. Therefore, they are regarded as complementary, and there is uncertainty on how they should be applied in clinical practice. This study compared hypertension management based on clinic and ABP measurements or on HBP measurements alone. METHODS Untreated subjects with elevated BP were randomized to treatment initiation and titration based on clinic and ABP measurements or on HBP measurements alone. Target organ damage was assessed at baseline and after 1 year of treatment with echocardiographic left ventricular mass index (primary endpoint), pulse wave velocity, and urinary albumin excretion. RESULTS A total of 145 subjects were randomized, and 116 completed the study (mean age = 50.7±10.5 years; 69 men (59%); mean follow-up = 13.4±1.4 months). There was no difference between the 2 arms in treatment-induced change in left ventricular mass index (mean difference = 0.50±1.11 g/m2; 95% confidence interval (CI) = -1.70 to 2.70). Moreover, there was no difference between the 2 arms in treatment-induced changes in pulse wave velocity (mean difference = -0.16±0.42 m/s; 95% CI = -0.99 to 0.66), urinary albumin excretion (mean difference = -0.85±4.28 mg/dl; 95% CI = -9.37 to 7.66), HBP and ABP levels, and hypertension control rates. CONCLUSIONS These data suggest that HBP monitoring alone is as reliable as combined clinic and ABP measurements in monitoring the effects of antihypertensive drug treatment on BP and preclinical target organ damage.
Collapse
Affiliation(s)
- George S Stergiou
- Hypertension Center, Third University Department of Medicine, Sotiria Hospital, Athens, Greece
| | | | | | | | | | | | | | | |
Collapse
|
3187
|
Affiliation(s)
- Giuseppe Schillaci
- From Dipartimento di Medicina, Università di Perugia, Perugia, Italy (G.S., G.P.); Struttura Complessa di Medicina Interna, Azienda Ospedaliero-Universitaria di Terni, Terni, Italy (G.S., G.P.); and Yazmonit Ltd, Eshtaol, Israel (B.G.)
| | - Giacomo Pucci
- From Dipartimento di Medicina, Università di Perugia, Perugia, Italy (G.S., G.P.); Struttura Complessa di Medicina Interna, Azienda Ospedaliero-Universitaria di Terni, Terni, Italy (G.S., G.P.); and Yazmonit Ltd, Eshtaol, Israel (B.G.)
| | - Benjamin Gavish
- From Dipartimento di Medicina, Università di Perugia, Perugia, Italy (G.S., G.P.); Struttura Complessa di Medicina Interna, Azienda Ospedaliero-Universitaria di Terni, Terni, Italy (G.S., G.P.); and Yazmonit Ltd, Eshtaol, Israel (B.G.)
| |
Collapse
|
3188
|
Rodríguez-Moran M, Guerrero-Romero F. Hypomagnesemia and prehypertension in otherwise healthy individuals. Eur J Intern Med 2014; 25:128-31. [PMID: 24035704 DOI: 10.1016/j.ejim.2013.08.706] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2013] [Revised: 08/22/2013] [Accepted: 08/25/2013] [Indexed: 12/15/2022]
Abstract
BACKGROUND Given the potential implications in the policies focused on the prevention of hypertension, we evaluate the relationship between low serum magnesium levels and prehypertension in otherwise healthy subjects. METHODS A cross-sectional study that enrolled 175 healthy men and non-pregnant women, 20 to 65 years of age was carried out. Type 2 diabetes, impaired fasting glucose, hypertension, chronic diarrhea, cancer, impaired renal function, as well as the intake of magnesium supplements in the previous six months, were the exclusion criteria. Hypomagnesemia was defined by serum magnesium concentration of <0.7 mmol/L and prehypertension by Systolic (S) and Diastolic (D) blood pressure (BP) of 120 to 139 and 80 to 89 mmHg. A multivariate logistic conditional forward analysis, adjusted by sex, age, alcohol consumption waist circumference, body mass index, fasting glucose and triglyceride levels was conducted to evaluate the association between hypomagnesemia and prehypertension. RESULTS Prehypertension was identified in 68 (13.2%) subjects who were compared with 107 (20.8%) control individuals without prehypertension. Individuals with prehypertension showed lower magnesium (0.73±0.20 vs. 0.77±0.21, p<0.001) and higher triglyceride levels (2.8±3.5 vs. 1.8±1.2, p=0.04) as compared with non-prehypertensive individuals. There were no other significant differences between the groups. The adjusted multivariate logistic conditional forward analysis showed a significant association between hypomagnesemia and prehypertension (OR 1.98; 95% CI 1.11-4.20, p=0.04). CONCLUSIONS Our finding suggests that low serum magnesium levels could play an important role in the pathophysiology of prehypertension in otherwise healthy subjects.
Collapse
Affiliation(s)
- Martha Rodríguez-Moran
- Biomedical Research Unit, Mexican Social Security Institute, Predio Canoas # 100, Col. Los Angeles, ZC 34067 Durango, Mexico
| | - Fernando Guerrero-Romero
- Biomedical Research Unit, Mexican Social Security Institute, Predio Canoas # 100, Col. Los Angeles, ZC 34067 Durango, Mexico.
| |
Collapse
|
3189
|
Agabiti-Rosei E, Manolis A, Zava D, Omboni S. Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients. Adv Ther 2014; 31:217-33. [PMID: 24415271 PMCID: PMC3930838 DOI: 10.1007/s12325-013-0090-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2013] [Indexed: 01/13/2023]
Abstract
INTRODUCTION In most treated patients with hypertension, a two or more drug combination is required to achieve adequate blood pressure (BP) control. In our study we assessed whether the combination of zofenopril + hydrochlorothiazide (HCTZ) was at least as effective as irbesartan + HCTZ in essential hypertensives with at least one additional cardiovascular risk factor, uncontrolled by a previous monotherapy. METHODS After a 2-week placebo washout, 361 treated hypertensive patients [office sitting diastolic BP (DBP), ≥90 mmHg], aged 18-75 years, were randomized double blind to 18-week treatment with zofenopril 30 mg plus HCTZ 12.5 mg or irbesartan 150 mg plus HCTZ 12.5 mg once daily, in an international, multicenter study. After the first 6 and 12 weeks, zofenopril and irbesartan doses could be doubled in non-normalized subjects. The primary study end point was the office sitting DBP reduction after 18 weeks of treatment. Secondary end points included office systolic BP (SBP), ambulatory BP and high sensitivity C-reactive protein (hs-CRP). RESULTS The between-treatment difference for office DBP averaged to +1.0 (95% CI -0.4, +0.8) mmHg (P = 0.150), the upper limit of the 95% confidence interval being inferior to the protocol-defined non-inferiority limit (3 mmHg). In the subset of patients with valid ambulatory BP, no difference in 24-h average DBP [n = 181; 6.7 (8.7, 4.6) zofenopril + HCTZ vs. 6.3 (8.8, 3.7) mmHg irbesartan + HCTZ, P = 0.810] and SBP reductions [11.7 (15.4, 8.0) vs. 12.6 (17.2, 8.0) mmHg, P = 0.758] were observed between the two treatment groups. hs-CRP was reduced by zofenopril + HCTZ [-0.52 (-1.05, 0.01) mg/L], while it was increased by irbesartan plus HCTZ [0.97 (0.29, 1.65) mg/L, P = 0.001 between treatments]. CONCLUSION In previously monotherapy-treated, uncontrolled patients with hypertension, zofenopril 30-60 mg + HCTZ 12.5 mg is as effective as irbesartan 150-300 mg plus HCTZ 12.5 mg, with the added value of a potential protective effect against vascular inflammation.
Collapse
Affiliation(s)
- Enrico Agabiti-Rosei
- Division of Medicine and Surgery, Spedali Civili and University of Brescia, Brescia, Italy
| | - Athanasios Manolis
- Asklepeion General Hospital of Voula, University of Athens, Athens, Greece
| | - Dario Zava
- Istituto Lusofarmaco d’Italia, Milan, Italy
| | | |
Collapse
|
3190
|
Galve E, Alegría E, Cordero A, Fácila L, Fernández de Bobadilla J, Lluís-Ganella C, Mazón P, de Pablo Zarzosa C, González-Juanatey JR. Update in cardiology: vascular risk and cardiac rehabilitation. ACTA ACUST UNITED AC 2014; 67:203-10. [PMID: 24774395 DOI: 10.1016/j.rec.2013.09.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2013] [Accepted: 09/26/2013] [Indexed: 12/11/2022]
Abstract
Cardiovascular disease develops in a slow and subclinical manner over decades, only to manifest suddenly and unexpectedly. The role of prevention is crucial, both before and after clinical appearance, and there is ample evidence of the effectiveness and usefulness of the early detection of at-risk individuals and lifestyle modifications or pharmacological approaches. However, these approaches require time, perseverance, and continuous development. The present article reviews the developments in 2013 in epidemiological aspects related to prevention, includes relevant contributions in areas such as diet, weight control methods (obesity is now considered a disease), and physical activity recommendations (with warnings about the risk of strenuous exercise), deals with habit-related psychosocial factors such as smoking, provides an update on emerging issues such as genetics, addresses the links between cardiovascular disease and other pathologies such as kidney disease, summarizes the contributions of new, updated guidelines (3 of which have recently been released on topics of considerable clinical importance: hypertension, diabetes mellitus, and chronic kidney disease), analyzes the pharmacological advances (largely mediocre except for promising lipid-related results), and finishes by outlining developments in the oft-neglected field of cardiac rehabilitation. This article provides a briefing on controversial issues, presents interesting and somewhat surprising developments, updates established knowledge with undoubted application in clinical practice, and sheds light on potential future contributions.
Collapse
Affiliation(s)
- Enrique Galve
- Servicio de Cardiología, Hospital Vall d'Hebron, Barcelona, Spain.
| | - Eduardo Alegría
- Servicio de Cardiología, Policlínica Gipuzkoa, San Sebastián, Guipúzcoa, Spain
| | - Alberto Cordero
- Departamento de Cardiología, Hospital Universitario de San Juan, Sant Joan d'Alacant, Alicante, Spain
| | - Lorenzo Fácila
- Servicio de Cardiología, Consorcio Hospital General de Valencia, Valencia, Spain
| | | | - Carla Lluís-Ganella
- Grupo de Epidemiología y Genética Cardiovascular, IMIM (Institut Hospital del Mar d'Investigacións Mèdiques), Barcelona, Spain
| | - Pilar Mazón
- Servicio de Cardiología, Hospital Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
| | | | - José Ramón González-Juanatey
- Servicio de Cardiología, Hospital Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
| |
Collapse
|
3191
|
|
3192
|
|
3193
|
Byrd JB, Bakris G, Jamerson K. The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension. Curr Hypertens Rep 2014; 16:419. [PMID: 24474031 DOI: 10.1007/s11906-014-0419-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommended a thiazide-like diuretic, alone or in combination with other antihypertensive drug classes, as initial therapy for hypertension. JNC 7, however, did not specify preferred combinations. The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial was completed five years after the JNC 7 and demonstrated a 20 % advantage in cardiovascular risk reduction when blood pressure was lowered using the single-pill combination of benazepril-amlodipine compared to benazepril-hydrochlorothiazide (Jamerson et al. 359(23):2417-28 [1]). This new and significant finding provided compelling evidence that the long-standing preference for diuretics as initial therapy could be refuted, but it may also be relevant to the lower-than-expected reduction in coronary disease related events (compared to stroke) observed for decades prior to the ACCOMPLISH approach to therapy. The JNC 8 panel members recently published their recommendations, and while the group did not recommend benazepril-hydrochlorothiazide over other combinations, they did highlight the findings of ACCOMPLISH, rating the primary ACCOMPLISH paper as "good." The American Society of Hypertension position paper and the European Hypertension Society guidelines endorse such combinations as a first-line agent for patients with stage 2 hypertension. We review the current position of ACCOMPLISH in the guidelines regarding treatment of stage 2 hypertension.
Collapse
Affiliation(s)
- James Brian Byrd
- Division of Cardiovascular Medicine, Department of Medicine, University of Michigan, 20-209W, North Campus Research Complex 2800 Plymouth Road, Ann Arbor, MI, 48109-2800, USA,
| | | | | |
Collapse
|
3194
|
Interarm difference in blood pressure: reproducibility and association with peripheral vascular disease. Int J Vasc Med 2014; 2014:841542. [PMID: 24616810 PMCID: PMC3927742 DOI: 10.1155/2014/841542] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Accepted: 12/09/2013] [Indexed: 11/17/2022] Open
Abstract
The present study aimed at examining the interarm difference in blood pressure and its use as an indicator of peripheral arterial disease (PAD). Data were included from consecutive patients referred from their general practitioner to our vascular laboratory for possible PAD aged 50 years or older without known cardiac disease, renal disease, or diabetes mellitus. 824 patients (453 women) with mean age of 72 years (range: 50-101) were included. 491 patients had a diagnosis of hypertension and peripheral arterial disease (PAD) was present in 386 patients. Systolic blood pressure was 143 ± 24 mmHg and 142 ± 24 mmHg on the right and left arm, respectively (P = 0.015). The interarm difference was greater in patients with hypertension (P = 0.002) and PAD (P < 0.0005). 443 patients were measured on two separate occasions and the interarm difference for systolic blood pressure was reproducible for differences >20 mmHg. This study confirmed the presence of a systematic but clinically insignificant difference in systolic blood pressure between arms. The interarm difference was larger in hypertension and PAD. Consistent lateralisation is present for differences ≥20 mmHg and an interarm difference >25 mmHg is a reliable indicator of PAD in the legs.
Collapse
|
3195
|
de Burgos-Lunar C, Jiménez-García R, Salinero-Fort MA, Gómez-Campelo P, Gil Á, Abánades-Herranz JC, Cárdenas-Valladolid J, del Cura-González I. Trends in hypertension prevalence, awareness, treatment and control in an adult type 2 diabetes Spanish population between 2003 and 2009. PLoS One 2014; 9:e86713. [PMID: 24475171 PMCID: PMC3903577 DOI: 10.1371/journal.pone.0086713] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Accepted: 12/10/2013] [Indexed: 01/13/2023] Open
Abstract
In patients with type 2 diabetes, the prevalence of hypertension is higher than in non-diabetic subjects. Despite the high cardiovascular risk involving hypertension in these patients, its prevalence and control are not well known. The aims of this study were: to estimate the hypertension prevalence, awareness, treatment and control in Spanish adults with type 2 diabetes attended in Primary Care; and to analyse its time trend from 2003 to 2009. A serial cross-sectional study from 2003 to 2009 was performed in 21 Primary Care Centres in Madrid. The study population comprised all patients with diagnosed type 2 diabetes in their computerised medical history. Overall annual prevalence during the period 2003-2009 was calculated from and according to sex and age groups. Linear trend tests, regression lines and coefficients of determination were used. In 2003 89.78% (CI 87.92-91.64) of patients with type 2 diabetes suffered hypertension and 94.76% (CI: 92.85-96.67) in 2009. This percentage was greater for women and for patients over 65 years old. 30% of patients suffered previously undiagnosed hypertension in 2003 and 23.1% in 2009. 97% of diagnosed patients received pharmacological treatment and 28.79% reached the blood pressure objective in 2009. The average number of antihypertensive drugs taken was 2.72 in 2003 and 3.27 in 2009. Only 5.2% of patients with type 2 diabetes show blood pressure levels below 130/80 mmHg. Although significant improvements have been achieved in the diagnosis and control of hypertension in people with type 2 diabetes, these continue to remain far from optimum.
Collapse
Affiliation(s)
- Carmen de Burgos-Lunar
- Clinical Epidemiology and Research Unit, Carlos III Hospital, Madrid, Spain
- Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, Spain
| | - Rodrigo Jiménez-García
- Preventive Medicine and Public Health Department, Rey Juan Carlos University, Alcorcón, Spain
| | - Miguel A. Salinero-Fort
- Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, Spain
- Biomedical Research Foundation, Carlos III Hospital, Madrid, Spain
| | | | - Ángel Gil
- Preventive Medicine and Public Health Department, Rey Juan Carlos University, Alcorcón, Spain
| | - Juan C. Abánades-Herranz
- Research Unit, Dirección Técnica de Docencia e Investigación, Gerencia Atención Primaria, Madrid, Spain
| | - Juan Cárdenas-Valladolid
- Research Unit, Dirección Técnica de Docencia e Investigación, Gerencia Atención Primaria, Madrid, Spain
| | - Isabel del Cura-González
- Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, Spain
- Preventive Medicine and Public Health Department, Rey Juan Carlos University, Alcorcón, Spain
- Research Unit, Dirección Técnica de Docencia e Investigación, Gerencia Atención Primaria, Madrid, Spain
| |
Collapse
|
3196
|
Lee BJ, Kim JY. A comparison of the predictive power of anthropometric indices for hypertension and hypotension risk. PLoS One 2014; 9:e84897. [PMID: 24465449 PMCID: PMC3900406 DOI: 10.1371/journal.pone.0084897] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Accepted: 11/19/2013] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND AND AIMS It is commonly accepted that body fat distribution is associated with hypertension, but the strongest anthropometric indicator of the risk of hypertension is still controversial. Furthermore, no studies on the association of hypotension with anthropometric indices have been reported. The objectives of the present study were to determine the best predictors of hypertension and hypotension among various anthropometric indices and to assess the use of combined indices as a method of improving the predictive power in adult Korean women and men. METHODS For 12789 subjects 21-85 years of age, we assessed 41 anthropometric indices using statistical analyses and data mining techniques to determine their ability to discriminate between hypertension and normotension as well as between hypotension and normotension. We evaluated the predictive power of combined indices using two machine learning algorithms and two variable subset selection techniques. RESULTS The best indicator for predicting hypertension was rib circumference in both women (p = <0.0001; OR = 1.813; AUC = 0.669) and men (p = <0.0001; OR = 1.601; AUC = 0.627); for hypotension, the strongest predictor was chest circumference in women (p = <0.0001; OR = 0.541; AUC = 0.657) and neck circumference in men (p = <0.0001; OR = 0.522; AUC = 0.672). In experiments using combined indices, the areas under the receiver operating characteristic curves (AUC) for the prediction of hypertension risk in women and men were 0.721 and 0.652, respectively, according to the logistic regression with wrapper-based variable selection; for hypotension, the corresponding values were 0.675 in women and 0.737 in men, according to the naïve Bayes with wrapper-based variable selection. CONCLUSIONS The best indicators of the risk of hypertension and the risk of hypotension may differ. The use of combined indices seems to slightly improve the predictive power for both hypertension and hypotension.
Collapse
Affiliation(s)
- Bum Ju Lee
- Medical Research Division, Korea Institute of Oriental Medicine, Yuseong-gu, Deajeon, Republic of Korea
| | - Jong Yeol Kim
- Medical Research Division, Korea Institute of Oriental Medicine, Yuseong-gu, Deajeon, Republic of Korea
| |
Collapse
|
3197
|
Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother 2014; 15:605-21. [DOI: 10.1517/14656566.2014.879117] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
3198
|
Yurtdaş M, Yaylali YT, Kaya Y, Özdemir M, Özkan İ, Aladağ N. Neutrophil-to-Lymphocyte Ratio May Predict Subclinical Atherosclerosis in Patients with Psoriasis. Echocardiography 2014; 31:1095-104. [DOI: 10.1111/echo.12511] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Affiliation(s)
- Mustafa Yurtdaş
- Department of Cardiology; Van Region Training and Research Hospital; Van Turkey
| | - Yalin T. Yaylali
- Department of Cardiology; School of Medicine; Pamukkale University; Denizli Turkey
| | - Yüksel Kaya
- Department of Cardiology; School of Medicine; Kafkas University; Kars Turkey
| | - Mahmut Özdemir
- Department of Cardiology; Van Region Training and Research Hospital; Van Turkey
| | - İlker Özkan
- Department of Dermatology; Lokman Hekim Hospital; Van Turkey
| | - Nesim Aladağ
- Department of Cardiology; Van Region Training and Research Hospital; Van Turkey
| |
Collapse
|
3199
|
Omboni S, Malacco E, Mallion JM, Fabrizzi P, Volpe M. Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies. High Blood Press Cardiovasc Prev 2014; 21:1-19. [PMID: 24435506 DOI: 10.1007/s40292-013-0037-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2013] [Accepted: 12/30/2013] [Indexed: 12/22/2022] Open
Abstract
Hypertension is a frequent condition among individuals over 65 years of age worldwide and is one of the most important risk factors for cardiovascular (CV) disease. Effective drug treatment of elderly hypertensives is usually associated with a marked reduction in CV morbidity and mortality. Among the different classes of antihypertensive agents, angiotensin receptor blockers (ARBs) and ACE-inhibitors are supposed to provide the best efficacy in lowering blood pressure (BP) and protecting target organ damage while featuring a good tolerability profile. However, up to date, few randomized clinical studies have directly compared the activity and safety of ARBs and ACE-inhibitors in elderly hypertensive patients. Aim of this review of published and unpublished pooled data from two recent randomized, double-blind, controlled trials, is to offer a comprehensive head-to-head comparison of the antihypertensive efficacy of the ARB olmesartan medoxomil vs. the ACE-inhibitor ramipril in a large study population including more than 1,400 hypertensive subjects aged 65-89 years with mild-to-moderate essential hypertension. The efficacy of the two drugs was separately evaluated in subgroups of patients classified according to the presence of metabolic syndrome, reduced renal function, CV risk level, gender, class of age, type of arterial hypertension and previous antihypertensive treatments. Olmesartan showed a greater efficacy than ramipril both in terms of clinic BP reduction and rate normalization. Olmesartan appeared significantly superior to ramipril in providing a more homogeneous and long-lasting 24-h BP control and maintaining an effective antihypertensive action in the last 6-h period from drug intake. In subgroups of patients with additional clinical conditions, olmesartan gave comparable, and in some cases greater, BP responses than those achieved with the ACE-inhibitor. The incidence of adverse events was similar for both drugs. Olmesartan may thus represent an effective alternative to ACE-inhibitors among first-line drug treatments for hypertension in older people.
Collapse
Affiliation(s)
- Stefano Omboni
- Italian Institute of Telemedicine, Via Colombera 29, 21048, Solbiate Arno (Varese), Italy,
| | | | | | | | | |
Collapse
|
3200
|
Duboz P, Boëtsch G, Gueye L, Macia E. Hypertension prevalence, awareness, treatment and control in Dakar (Senegal). J Hum Hypertens 2014; 28:489-93. [PMID: 24430710 DOI: 10.1038/jhh.2013.142] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2013] [Revised: 11/26/2013] [Accepted: 12/02/2013] [Indexed: 01/16/2023]
Abstract
The prediction of risk profile trends associated with non-communicable diseases in developing countries is among the greatest global health challenges. The aim of this study is to estimate prevalence, awareness, treatment and control of hypertension in Dakar (Senegal). This study was carried out between January and June 2009 on a population sample of 600 individuals living in the department of Dakar. This sample was constructed using the quota method in order to strive for representativeness. Sociodemographic characteristics, hypertension, hypertension awareness, treatment and control, and body mass index of individuals were collected during face-to-face interviews. Statistical analyses used were χ2-tests and binary logistic regressions. Prevalence of hypertension was 27.50%. Prevalence of awareness, treatment and control among hypertensives were 27.88%, 16.97% and 5.45%, respectively. Logistic regression showed that the prevalence, awareness and treatment of hypertension increased with increasing age. Overweight and obese subjects were more often hypertensive but did not differ from others in awareness and treatment. This could be linked to the social valorization of stoutness in West Africa, which explains that excess weight is not perceived as a risk factor for hypertension. In conclusion, given the very low rates of awareness, treatment and control in our sample, developing strategies for averting a hypertension epidemic must be a priority objective.
Collapse
Affiliation(s)
- P Duboz
- UMR 7268 ADèS, Aix-Marseille Université/EFS/CNRS, Faculté de Médecine Secteur Nord, Boulevard Pierre Dramard, Marseille, France
| | - G Boëtsch
- UMI 3189 Environnement, Santé, Sociétés, CNRS/Université Cheikh Anta Diop/Université de Bamako/CNRST, Laboratoire de Physiologie exploratoire et fonctionnelle, Faculté de Médecine de Dakar, Université Cheikh Anta Diop, Dakar, Senegal
| | - L Gueye
- UMI 3189 Environnement, Santé, Sociétés, CNRS/Université Cheikh Anta Diop/Université de Bamako/CNRST, Laboratoire de Physiologie exploratoire et fonctionnelle, Faculté de Médecine de Dakar, Université Cheikh Anta Diop, Dakar, Senegal
| | - E Macia
- UMI 3189 Environnement, Santé, Sociétés, CNRS/Université Cheikh Anta Diop/Université de Bamako/CNRST, Laboratoire de Physiologie exploratoire et fonctionnelle, Faculté de Médecine de Dakar, Université Cheikh Anta Diop, Dakar, Senegal
| |
Collapse
|